Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL172902 | 0.83 | CHEK1 (0.67) | KDRCHEK1 | |
| SCHEMBL142580 | 0.83 | CHEK1 (0.59) | KDRCHEK1 | |
| Hydrochloric Acid SCHEMBL5677881 | 0.82 | CHEK1 (0.66) | KDRCHEK1 | |
| SCHEMBL143698 | 0.80 | NPSR1 (0.43) | KDRCHEK1NPSR1CDK5CDK5R1 | |
| SCHEMBL5079425 | 0.80 | CHEK1 (0.62) | KDRCHEK1 | |
| SCHEMBL145628 | 0.80 | KDR (0.44) | KDRCHEK1KDM4E | |
| SCHEMBL146796 | 0.78 | KDR (0.60) | KDRCHEK1 | |
| SCHEMBL14311030 | 0.78 | NPSR1 (0.50) | NPSR1KDM4EALOX15HTTCYP2D6 | |
| SCHEMBL5082073 | 0.76 | KDR (0.76) | KDRCHEK1 | |
| Tert-Butyl Formate SCHEMBL27486793 | 0.76 | CHEK1 (0.57) | KDRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927293-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-08-09 | — | — | US | claimed |
| US-20040192725-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-09-30 | — | — | US | claimed |
| WO-2003020276-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | claimed |
| US-20140221455-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | Verva Pharmaceuticals, Inc. (AU) | 2014-08-07 | — | — | US | disclosed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| US-6927293-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-08-09 | — | — | US | disclosed |
| WO-2005065686-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | ADIPOGEN PHARMACEUTICALS PTY LIMITED (AU) | 2005-07-21 | — | — | WO | disclosed |
| US-20040192725-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192725-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885CHEK1 499/4885NPSR1 4046/4885 |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885NPSR1 3871/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885NPSR1 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.